Literature DB >> 15505264

Infliximab and serious hematologic events.

Cynthia Phelan1, Eric Wooltorton.   

Abstract

Mesh:

Substances:

Year:  2004        PMID: 15505264      PMCID: PMC526325          DOI: 10.1503/cmaj.1041597

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  5 in total

1.  Adverse reactions to TNF-alpha inhibitors in rheumatoid arthritis.

Authors:  Richard Day
Journal:  Lancet       Date:  2002-02-16       Impact factor: 79.321

Review 2.  Tumour necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection.

Authors:  Richard Long; Michael Gardam
Journal:  CMAJ       Date:  2003-04-29       Impact factor: 8.262

3.  Use of biologics for rheumatoid arthritis tempered by concerns over safety, cost.

Authors:  Sarah Pressman Lovinger
Journal:  JAMA       Date:  2003-06-25       Impact factor: 56.272

4.  Severe neutropenia and thrombocytopenia associated with infliximab.

Authors:  Francesc Vidal; Ramón Fontova; Cristóbal Richart
Journal:  Ann Intern Med       Date:  2003-08-05       Impact factor: 25.391

5.  Pancytopenia in a patient with scleroderma treated with infliximab.

Authors:  Y Menon; E Cucurull; L R Espinoza
Journal:  Rheumatology (Oxford)       Date:  2003-10       Impact factor: 7.580

  5 in total
  2 in total

1.  Combination of infliximab with thiopurines significantly reduces white cell and neutrophil counts in inflammatory bowel disease patients.

Authors:  V Parihar; O Maceneaney; S Maguire; C Garry; M O'Sullivan; M Kennedy; K Safaya; C Smyth; R Farrell
Journal:  Ir J Med Sci       Date:  2016-05-30       Impact factor: 1.568

2.  Antitumor necrosis factor-induced neutropenia: a case report with double positive rechallenges.

Authors:  E Montané; M Sallés; A Barriocanal; E Riera; J Costa; X Tena
Journal:  Clin Rheumatol       Date:  2006-10-10       Impact factor: 2.980

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.